CG Oncology (CGON) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed CG Oncology (CGON) over the past year, gaining 245.2% versus a gain of 64.2%. CG Oncology is the larger company by market cap ($5.53 billion vs $2.63 billion), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | MBX |
|---|---|---|
| Share price | $62.38 | $54.54 |
| Market cap | $5.53B | $2.63B |
| 1-day change | -1.98% | -4.18% |
| YTD return | +50.24% | +72.92% |
| 1-year return | +64.16% | +245.19% |
| EPS (TTM) | $-2.69 | $-2.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | — |
| Revenue growth (YoY) | +254.70% | — |
| Net income (latest FY) | $-161.00M | $-87.00M |
| Operating margin | -4722.13% | — |
| Net margin | -3985.02% | — |
| 52-week high | $80.97 | $72.64 |
| 52-week low | $35.80 | $12.94 |
| Distance from 52-week high | -22.96% | -24.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.01% | +72.90% |
| Average volume | 891.79K | 556.72K |
| Shares outstanding | 88.64M | 48.16M |
| Employees | 142 | 63 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CG Oncology is about 2.1 times larger than MBX Biosciences by market value ($5.53B vs $2.63B).
- MBX has outperformed CGON by 181.0 percentage points over the past year.
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Healthcare · Biotechnology · 142 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Healthcare · Biotechnology · 63 employees
CGON vs MBX FAQ
Which is bigger, CG Oncology or MBX Biosciences?
CG Oncology (CGON) is larger, with a market capitalization of $5.53B compared with $2.63B for MBX Biosciences (MBX).
Which stock has performed better over the past year, CGON or MBX?
MBX returned +245.19% over the past 12 months, compared with +64.16% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.